FdaApprovalPulse: Drug efficacy supplement (new indication or use)
76 fdaApprovalPulse: Drug efficacy supplement (new indication or use) are listed from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), dated 2026-05-08 to 2026-10-26; the most frequent is ELI LILLY AND CO with 11. Data last updated 2026-11-03; each record links to its official source and a full report.
Data as of · Compiled by Zalwin from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)
Includes: Sponsor, Product, Approval, Decided, official source URL and score · Card, Apple Pay, Google Pay or Link via Stripe
76 records from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), dated 2026-05-08 to 2026-10-26. Most frequent: ELI LILLY AND CO (11). Each record links to a full report and the official source.
Last updated 2026-11-03. Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration).
Get new FdaApprovalPulse records by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
- ELI LILLY AND CO (11)
- GENENTECH INC (5)
- NOVARTIS (5)
- PFIZER (4)
- ABBVIE INC (3)
How do I get new fdaApprovalPulse: Drug efficacy supplement (new indication or use) by email?
Search, filter and export these records, or get alerts when new ones appear.
What are the top fdaApprovalPulse: Drug efficacy supplement (new indication or use) right now?
| Record | Product | Approval | Decided |
|---|---|---|---|
| PFIZER | TALZENNA | Drug efficacy supplement (new indication or use) | 2026-10-26 |
| PFIZER | TALZENNA | Drug efficacy supplement (new indication or use) | 2026-10-26 |
| ABBVIE INC | SKYRIZI | Drug efficacy supplement (new indication or use) | 2026-10-23 |
| NOVO NORDISK INC | AWIQLI FLEXTOUCH | Drug efficacy supplement (new indication or use) | 2026-10-23 |
| PHARMACOSMOS | MONOFERRIC | Drug efficacy supplement (new indication or use) | 2026-10-23 |
| GLAXOSMITHKLINE | JEMPERLI | Drug efficacy supplement (new indication or use) | 2026-10-19 |
| GENENTECH | ENSPRYNG | Drug efficacy supplement (new indication or use) | 2026-10-15 |
| NOVARTIS PHARMS CORP | COSENTYX | Drug efficacy supplement (new indication or use) | 2026-10-15 |
| UCB INC | ZILBRYSQ | Drug efficacy supplement (new indication or use) | 2026-10-15 |
| ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU | ANKTIVA | Drug efficacy supplement (new indication or use) | 2026-10-14 |
| ELI LILLY AND CO | OLUMIANT | Drug efficacy supplement (new indication or use) | 2026-10-09 |
| AMGEN INC | REPATHA | Drug efficacy supplement (new indication or use) | 2026-10-09 |
| GENENTECH INC | TECENTRIQ HYBREZA | Drug efficacy supplement (new indication or use) | 2026-10-08 |
| GENENTECH INC | TECENTRIQ | Drug efficacy supplement (new indication or use) | 2026-10-08 |
| SEAGEN | TUKYSA | Drug efficacy supplement (new indication or use) | 2026-10-07 |
| NOVARTIS | 🔒 Unlock all 76 records → | ||
| BRISTOL | 🔒 Unlock all 76 records → | ||
| GENENTECH | 🔒 Unlock all 76 records → | ||
Browse 35 more matching record reports
- NOVARTIS
- BRISTOL
- GENENTECH
- ELI LILLY AND CO
- EISAI INC
- ELI LILLY AND CO
- INTRABIO
- ELI LILLY AND CO
- ASTRAZENECA
- NUVATION
- ASTRAZENECA
- PHARMING
- BIOFRONTERA
- BAYER HEALTHCARE
- PHARMAESSENTIA CORP
- ELI LILLY AND CO
- ELI LILLY AND CO
- GILEAD SCIENCES INC
- GILEAD SCIENCES INC
- ELI LILLY AND CO
- BEIGENE
- BIOCON BIOLOGICS INC
- NOVARTIS
- ASTELLAS
- ASTELLAS
- SCPHARMACEUTICALS
- MUNDIPHARMA
- NOVARTIS
- SUN PHARMA GLOBAL
- ELI LILLY AND CO
- ELI LILLY AND CO
- ELI LILLY AND CO
- EISAI INC
- ASTELLAS
- NOVARTIS
More records in this hub: page 2
Browse all FdaApprovalPulse record reports
Which related categories and locations should I check?
Browse by approval type
Drug labeling or REMS supplement (1174) PMA supplement (device change) (367) Generic drug approval (ANDA) (194) Drug manufacturing (CMC) supplement (55) New drug application (NDA) (40) PMA original approval (new class III device) (24) Biologic license (BLA) (17) Other drug supplement (12)
Browse by sponsor state (devices)
California (110) Minnesota (61) Massachusetts (37) Oregon (20) Arizona (18) Texas (18) Illinois (9) Maryland (9) Tennessee (8) Pennsylvania (7) Florida (6) Washington (6) Missouri (5) Wisconsin (5) Colorado (4) Connecticut (4) Georgia (4) Indiana (4) New Jersey (4) New York (4) North Carolina (3) Ohio (3)
Frequently asked questions
How many fdaApprovalPulse: Drug efficacy supplement (new indication or use) are listed?
76 records from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration), last refreshed automatically. The most recent is dated 2026-10-26.
Can I get alerts for Drug efficacy supplement (new indication or use)?
Yes. FdaApprovalPulse can email you new records matching this filter; plans are listed on the FdaApprovalPulse page.
Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration). Informational only. RSS feed of new records